Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma

Diagnostic Molecular Pathology

Volumn 7, Issue 6, 1998, Pages 295-301

  Bot, Fredrik J ^a   Sleddens, Hein F B M ^b   Dinjens, Winand N M ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cystosarcoma phyllodes; Loss of heterozygosity; Microsatellite analysis; Polymerase chain reaction; Single strand conformation polymorphism; TP53

Indexed keywords

MICROSATELLITE DNA; PROTEIN P53;

ARTICLE; CHROMOSOME 17P; CODON; CYSTOSARCOMA PHYLLOIDES; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; HUMAN TISSUE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADULT; BREAST NEOPLASMS; CODON; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; FEMALE; FIBROADENOMA; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEG; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PHYLLODES TUMOR; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032421828     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-199812000-00002     Document Type: Article

References (24)

1. Arrowsmith CH, Morin P. New insights into tp53 function from structural studies. Oncogene 1996;12:1379-85.
2. Cohn-Cedermark G, Rutqvist LE, Rosendahl I, Silfversward C. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer 1991;68:2017-22.
3. De Vita VT, Hellman S, Rosenberg SA. Cancer: Principles and practice of oncology. Philadelphia: Lippincott-Raven Publishers, 1997.
4. Eeles RA, Warren W, Knee G, Bartek J, Averill D, Stratton MR, Blake PR, Tait DM, Lane DP, Easton DF, et al. Constitutional mutation in exon 8 of the tp53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. Oncogene 1993;8:1269-76.
5. Griesser H. Applied molecular genetics in the diagnosis of malignant non-Hodgkin's lymphoma. Diagn Mol Pathol 1993;2:177-91.
6. Grimes MM. Cystosarcoma phyllodes of the breast: histologic features, flow cytometric analysis, and clinical correlations. Mod Pathol 1992;5:232-9.
7. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris CC, Montesano R. IARC Database of tp53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res 1998;26:207-15.
8. Hawkins RE, Schofield JB, Fisher C, Wiltshaw E, McKinna JA. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer 1992;69:141-7.
9. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B, Levine AJ. Mutant tp53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1990;1:571-80.
10. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 1992;5:89-90.
11. Keelan PA, Myers JL, Wold LE, Katzmann JA, Gibney DJ. Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. Hum Pathol 1992;23:1048-54.
12. Kim CJ, Kim WH. Patterns of tp53 expression in phyllodes tumors of the breast - an immunohistochemical study. J Korean Med Sci 1993;8:325-8.
13. Knowles DM. Immunophenotypic and immunogenotypic approaches useful in distinguishing benign and malignant lymphoid proliferations. Semin Oncol 1993;20:583-610.
14. MacGeoch C, Turner G, Bobrow LG, Barnes DM, Bishop DT, Spurr NK. Heterogeneity in Li-Fraumeni families: tp53 mutation analysis and immunohistochemical staining. J Med Genet 1995; 32:186-90.
15. Malkin D. tp53 and the Li-Fraumeni syndrome. Cancer Genet Cytogenet 1993;66:83-92.
16. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 1994;91:9871-5.
17. Mazoyer S, Lalle P, Moyret-Lalle C, Marcais C, Schraub S, Frappaz D, Sobol H, Ozturk M. Two germ-line mutations affecting the same nucleotide at codon 257 of tp53 gene, a rare site for mutations. Oncogene 1994;9:1237-9.
18. Ranzani GN, Luinetti O, Padovan LS, Calistri D, Renault B, Burrel M, Amadori D, Fiocca R, Solcia E. tp53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 1995;4:223-31.
19. Rosen PP. Breast Pathology. Philadelphia: Lippincott-Raven Publishers, 1997.
20. Sambrook J, Fritsch EF, Maniatis T. DNA sequencing. In: Nolan C ed. Molecular cloning, a laboratory manual.: Cold Spring Harbor Laboratory Press, 1989.
21. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 1997;74:5463-7.
22. Sleddens HF, Oostra BA, Brinkmann AO, Trapman J. Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res 1992;20:1427.
23. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 1997;57:3245-52.
24. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989;44:388-96.